Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more 2019 The Lancet 3175 citations